Supervalu files US antitrust claims against Takeda, TWi Pharmaceuticals over Dexilant
MLex Summary: Supervalu filed a US complaint accusing Takeda Pharmaceutical and Twi Pharmaceuticals of entering into an illegal reverse payment agreement to restrain competition in the US market for Dexilant and its...To view the full article, register now.
Already a subscriber? Click here to view full article